GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » YoY EBITDA Growth

Andros Pharmaceuticals Co (ROCO:6917) YoY EBITDA Growth : 15.24% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Andros Pharmaceuticals Co's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 15.24%.

Andros Pharmaceuticals Co's EBITDA per Share for the six months ended in Dec. 2024 was NT$-0.95.

Andros Pharmaceuticals Co YoY EBITDA Growth Historical Data

The historical data trend for Andros Pharmaceuticals Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co YoY EBITDA Growth Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial 41.65 -5.90 5.02 -62.21 5.04

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.92 -9.16 -120.00 -13.81 15.24

Andros Pharmaceuticals Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Andros Pharmaceuticals Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-1.602--1.687)/ | -1.687 |
=5.04 %

Andros Pharmaceuticals Co's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-0.951--1.122)/ | -1.122 |
=15.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » YoY EBITDA Growth
Comparable Companies
ROCO:6999 ROCO:6652 ROCO:6549 ROCO:6827 ROCO:6662 ROCO:6876 ROCO:4170 ROCO:6709 ROCO:6610 ROCO:4192 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Website
http://www.androspharma.com
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co Headlines

No Headlines